First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
Unit of Infectious Diseases, Dept of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy These authors contributed equally.
Marina
M
Tadolini
Delek Hospital, Dharamshala, India These authors contributed equally.
Rangjung Dolma
RD
Lingtsang
Division of Infection, Barts Health NHS Trust, London, UK These authors contributed equally.
Simon
S
Tiberi
Amity Health Consortium, Johannesburg, South Africa These authors contributed equally.
Martin
M
Enwerem
Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy Public Health Consulting Group, Lugano, Switzerland These authors contributed equally.
Lia
L
D'Ambrosio
Delek Hospital, Dharamshala, India.
Tsetan Dorji
TD
Sadutshang
Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy.
Rosella
R
Centis
Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy giovannibattista.migliori@fsm.it.
Giovanni Battista
GB
Migliori
D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D064687:Diarylquinolines / Q000627:therapeutic use*; D054908:Extensively Drug-Resistant Tuberculosis / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D009593:Nitroimidazoles / Q000627:therapeutic use*; D010080:Oxazoles / Q000627:therapeutic use*
D000995:Antitubercular Agents; D064687:Diarylquinolines; D009593:Nitroimidazoles; C516022:OPC-67683; D010080:Oxazoles; C493870:bedaquiline